Please find attached the Q1 FY 27 Financial Results

Date: 04/08/2026 National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 Symbol: MOREPENLAB Scrip Code: 500288 Subject: Outcome of the meeting of the Board of Directors of the company Dear Sir/ Madam, This is to inform you that the Board of Directors of the company, in their meeting held today i.e., Tuesday, 4th August 2026 (commenced at 11.30 a.m. and concluded at 1.20 p.m.), have, considered and approved, inter-alia: 1. Un-audited standalone & consolidated financial results of the company for the quarter ended 30th June 2026, based on the recommendation of Audit Committee, in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’). The financial results along with the limited review reports of the auditors of the company, are enclosed herewith as Annexure-A. 2. Record date as Saturday, 19th September 2026, for the purpose of determining the members eligible to receive final dividend for the financial year ended 31st Match 2026, if approved by members at their 41st Annual General Meeting (‘AGM’), in accordance with Regulation 42 of Listing Regulations. 3. Subject to the approval of members of the company at the forthcoming 41st AGM, extension of approved timeline for hiving off Medical Devices Business, a material related party transaction, into Morepen Medipath Limited (formerly, Morepen Medtech Limited), a subsidiary company, as a going concern on slump sale basis. 4. Subject to the approval of members at the 41st AGM of the company, re-appointment of Mr. Sushil Suri (DIN: 00012028) as the Chairman & Managing Director of the company, pursuant to the recommendation of the Nomination and Remuneration Committee, for a further period of three (3) years effective from 20th October 2026 to 19th October 2029 (both days inclusive). The details as required under the SEBI Listing Regulations read with SEBI master circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026, is given in the Annexure-B. Morepen Laboratories Limited CIN NO. L24231 HP1984PLC006028 Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com 5. The notice of the 41st AGM of members of the company, scheduled to be held on Saturday, 26th September 2026 through video conferencing / other audio-visual means, in accordance with the applicable circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India. You are requested to take the same on record. Thanking you, Yours faithfully, For Morepen Laboratories Limited Vipul Kumar Srivastava Company Secretary F-12148 Encl.: a/a. Morepen Laboratories Limited CIN NO. L24231 HP1984PLC006028 Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com Annexure A S.P. Babuta and Associates Chartered Accountants #240, Sector 21-A, Chandigarh-160022, Tel: 91172 2704943, 2713814, Email ID: spb,1bum@hocmail.com, Website: www.babuta.com INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF MOREPEN LABORATORIES LIMITED 1. We have reviewed the accompanying statement of consolidated financial results of Morepen Laboratories Limited (the "Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as the ("Group") for the quarter ended June 30, 2026 (the "Statement"), being submitted by the Parnnt pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"). 2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable. 4, This Statement includes the results of the following Group entities: Parent: Morepen Laboratories Limited Indian Subsidiary: a) Morepen Devices Limited S.P. Babuta and Associates b) Morepen Rx Ltd. c) Morepen Medipath Limited (formerly known as Morepen Med tech Limited) d) Sigmacheck Health Private Limited Foreign Subsidiary: a) Morepen Bio Inc., USA b) Morepen Labs FZE., UAE (formerly known as Morepen Labs FZCO) c) Morepen Medical Equipment Trading L.L.C., UAE 5. Based on our review conducted and procedures performed as stated in paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"), including the manner in which it is to be disclosed, or that it contains any material misstatement. 6. We did not review the interim financial results of five subsidiaries i.e. Morepen Devices Limited, Morepen Rx Ltd., Morepen Bio Inc., Morepen Medical Equipment Trading L.L.C and Morepen Labs FZE, included in the statement, whose interim financial results reflect total profit/(loss) after tax (before consolidation adjustments) of Rs.238.71 Lakhs (comprising of total revenue of Rs.8045.37 Lakhs and total expenses of Rs.7803.83 Lakhs) and total comprehensive income (before consolidation adjustments) of Rs.238.71 Lakhs for the quarter ended June 30, 2026. The interim financial results of the Indian subsidiaries have been reviewed by their auditors whose report has been furnished to us by the Parent's management and our conclusion on th [Showing first 8,000 characters — download PDF for full document]